Alendronic acid
Alendronic acid has been studied in 2 papers since 2023: 1 observational study in people. The newest paper, Aug 2, 2024: “Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates”.
- Humans1
- In silico1
Latest
Internal and Emergency Medicine
Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates
Study of 60 peopleDenosumab
The Lancet Regional Health Europe
Explaining declining hip fracture rates in Norway: a population-based modelling study
Computational studyHip fracture